GlassScriptPhysician profile
Thomas A Freichels
NPI 1457394991
$3,599.67
in general payments reported to CMS, 2019-2025
27 companies · $949 in 2025
The $949 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $359 · 2022: $351 · 2023: $722 · 2024: $1,218 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,589 · Consulting Fee: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,589.27 |
| Consulting Fee | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $681.52 | 2021-2025 | Breztri, Fasenra, Airsupra |
| Harmony Biosciences LLC | $654.34 | 2022-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $331.26 | 2021-2025 | |
| Inspire Medical Systems, INC. | $322.42 | 2024-2025 | Inspire |
| Glaxosmithkline, LLC. | $236.12 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $196.52 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.92 | 2021-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| United Therapeutics Corporation | $184.38 | 2022-2025 | Tyvaso, Tyvaso |
| Avadel Cns Pharmaceuticals, LLC | $171.93 | 2024 | Lumryz |
| Insmed, INC. | $87.96 | 2023-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $72.63 | 2024-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $64.11 | 2023-2025 | Opsumit, Uptravi |
| Pfizer INC. | $55.48 | 2021-2023 | |
| Philips North America LLC | $50.23 | 2021-2025 | Vest Therapy Und |
| Baxter Healthcare | $32.76 | 2023-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $31.42 | 2022-2024 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $29.30 | 2021-2022 | |
| Grifols USA, LLC | $27.51 | 2024 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $25.84 | 2022 | |
| Pulmonx Corporation | $23.61 | 2023 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Sandoz INC. | $22.46 | 2025 | Treprostinil |
| Idorsia Pharmaceuticals US INC | $20.93 | 2023 | Quviviq |
| Genentech USA, INC. | $20.21 | 2021 | |
| Lilly USA, LLC | $17.76 | 2025 | |
| Mylan Specialty L.P. | $16.52 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.89 | 2022 | |
| Amgen INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Freichels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.